A Phase 1 interventional study of Ruxolitinib Cream in Hidradenitis Suppurativa, sponsored by Incyte Corporation. Recruiting at 21 sites in United States. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment
Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 11th largest by planned enrollment, is one of 4 that started in 2025, is the only one in phase 1, and was the 11th registered.
284 studies on the registry are indexed under Hidradenitis Suppurativa; 87 are open to participants now.
Browse Hidradenitis Suppurativa studies →3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Canada
Incyte Corporation · Sites in United States, Argentina, Australia and 17 more countries
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 12 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 24 is below the median of 45 across 199 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 391 across the 12 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
2 of the studies in Hidradenitis Suppurativa by Incyte Corporation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT07049575Incyte CorporationStudy to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa | 2026-12-09 |
Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
Drug: Ruxolitinib Cream
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Defined as adverse events reported for the first time or worsening of a pre-existing event after the first application of study drug.
Time frame: Up to 24 weeks
Number of participants with TEAEs leading to treatment interruption, discontinuation
Number of participants with TEAEs leading to dose interruption or discontinuation
Time frame: Up to 24 weeks
Pharmacokinetics Parameter (PK): Cmax of INCB018424
Defined as maximum observed plasma concentration of INCB018424.
Time frame: Up to 24 weeks
Pharmacokinetics Parameter: Tmax of INCB018424
Defined as the time to reach the maximum plasma concentration of INCB018424.
Time frame: Up to 24 weeks
Pharmacokinetics Parameter: AUC 0-12 of INCB018424
Defined as the area under the plasma or serum concentration-time curve from Hour 0 to 12 hours of INCB018424.
Time frame: Up to 24 weeks
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.
Of 20 phase 1 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib